BostonGene Exhibiting Multimodal AI Platform for Progress in Drug Development at 2025 ASCO Annual Conference
At the 2025 ASCO Annual Meeting, scheduled for May 31 - June 3 at McCormick Place Convention Center in Chicago, IL, BostonGene will present six groundbreaking studies that showcase the transformative potential of their AI-integrated multiomic platform in advancing precision oncology and personalized treatment strategies.
The studies, which will be published online in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings, highlight BostonGene's commitment to improving molecular diagnosis, guiding targeted therapies, and enhancing outcomes through data-informed treatment strategies.
One of the key findings from the studies is the ability of BostonGene's AI-powered multiomic platform to enable deep molecular characterization of tumors and immune profiles. This capability supports the identification of distinct molecular subtypes of cancers such as invasive lobular carcinoma and small-cell lung cancer (SCLC), facilitating more precise patient stratification.
In collaboration with the SWOG Cancer Research Network, BostonGene is driving personalized treatment approaches by enrolling up to 900 patients to assign therapies based on the AI-identified molecular subtypes. Early findings from related trials, such as the SWOG S1929 study, demonstrate promising improvements in progression-free survival by targeting the vulnerabilities of specific SCLC subtypes.
BostonGene's approach is poised to accelerate translational insights to inform future oncology drug development. The platform offers a roadmap for biomarker-driven treatments that could revolutionize cancer care beyond lung cancer, by building and validating precision therapy frameworks across cancer types.
Across six studies, BostonGene will demonstrate how its platform uncovers novel biomarkers, refines patient stratification, and predicts therapeutic response across various tumor types. The studies include the clinical utility of the BostonGene Tumor Portrait test in guiding treatment selection for castrate-resistant prostate cancer based on tumor microenvironment-related gene signatures.
Another study, conducted in collaboration with MD Anderson Cancer Center, presents unique histologic and molecular findings in invasive lobular carcinoma. Another focuses on identifying distinct molecular patterns in various sarcoma subtypes that correlate with survival outcomes.
In addition, BostonGene will reveal novel hotspots of gene fusions in Liposarcoma samples and uncover the tumor microenvironment in Cancer of Unknown Primary. The study "Tertiary lymphoid structures and their association with immune checkpoint inhibitor response and survival outcomes in patients with non-small cell lung cancer" leverages BostonGene's AI-driven Kassandra deconvolution algorithm to analyze transcriptomic data from patients with non-small cell lung cancer.
The findings underscore the importance of precision medicine in managing cancer subtypes that are resistant to traditional interventions. The study identifies unique tertiary lymphoid structures within the tumor microenvironment that may serve as predictive and prognostic biomarkers. The study also reveals correlations between clinical factors, the tumor microenvironment, and immunotherapy response with survival outcomes in CUP.
Lev Bedniagin, MD, from BostonGene, will present the studies at booth #15147 during the ASCO Annual Meeting. The presentations collectively demonstrate how BostonGene's AI-integrated platform is transforming precision oncology by improving molecular diagnosis, guiding targeted therapies, and enhancing outcomes through personalized, data-informed treatment strategies.
- At the ASCO Annual Meeting, BostonGene's studies will showcase the transformative potential of their AI-integrated multiomic platform in advancing precision oncology, particularly in the identification of distinct molecular subtypes of cancers such as invasive lobular carcinoma and small-cell lung cancer (SCLC).
- The studies will reveal promising improvements in progression-free survival by targeting the vulnerabilities of specific SCLC subtypes, through personalized treatment approaches in collaboration with the SWOG Cancer Research Network.
- BostonGene's AI-driven platform will also uncover novel biomarkers, refine patient stratification, and predict therapeutic response across various tumor types, including non-small cell lung cancer, prostate cancer, sarcoma subtypes, Liposarcoma samples, and Cancer of Unknown Primary.
